Leqembi Dosage/Direction for Use

Patient Selection: Confirm the presence of amyloid beta pathology prior to initiating treatment [see Pharmacology: Mechanism of Action under Actions].
Dosing Information: The recommended dosage of LEQEMBI is 10 mg/kg that must be diluted then administered as an intravenous infusion over approximately one hour, once every two weeks.
If an infusion is missed, administer the next dose as soon as possible.
Monitoring and Dosing Interruption for Amyloid Related Imaging Abnormalities: LEQEMBI can cause amyloid related imaging abnormalities -edema (ARIA-E) and -hemosiderin deposition (ARIA-H) [see Amyloid Related Imaging Abnormalities under Precautions].
Monitoring for ARIA: Obtain a recent baseline brain magnetic resonance imaging (MRI) prior to initiating treatment with LEQEMBI. Obtain an MRI prior to the 5^th, 7^th, and 14^th infusions. If a patient experiences symptoms suggestive of ARIA, clinical evaluation should be performed, including an MRI if indicated.
Recommendations for Dosing Interruptions in Patients with ARIA: ARIA-E: The recommendations for dosing interruptions for patients with ARIA-E are provided in Table 4. (See Table 4.)

Click on icon to see table/diagram/image

ARIA-H: The recommendations for dosing interruptions for patients with ARIA-H are provided in Table 5. (See Table 5.)

Click on icon to see table/diagram/image

In patients who develop intracerebral hemorrhage greater than 1 cm in diameter during treatment with LEQEMBI, suspend dosing until MRI demonstrates radiographic stabilization and symptoms, if present, resolve. Use clinical judgement in considering whether to continue treatment after radiographic stabilization and resolution of symptoms or permanently discontinue LEQEMBI.
Administration Instructions: Visually inspect the LEQEMBI diluted solution for particles or discoloration prior to administration. Do not use if it is discolored, or opaque or foreign particles are seen.
Prior to infusion, allow the LEQEMBI diluted solution to warm to room temperature.
Infuse the entire volume of the LEQEMBI diluted solution intravenously over approximately one hour through an intravenous line containing a terminal low-protein binding 0.2 micron in-line filter. Flush infusion line to ensure all LEQEMBI is administered.
Monitor for any signs or symptoms of an infusion-related reaction. The infusion rate may be reduced, or the infusion may be discontinued, and appropriate therapy administered as clinically indicated. Consider pre-medication at subsequent dosing with antihistamines, non-steroidal anti-inflammatory drugs, or corticosteroids [see Infusion-Related Reactions under Precautions].